A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Saved in:
| Title: | A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. |
|---|---|
| Authors: | Curtin, Francois1,2 (AUTHOR) fc@geneuro.com, Champion, Bernard3 (AUTHOR), Davoren, Peter4 (AUTHOR), Duke, Sally5 (AUTHOR), Ekinci, Elif I.6 (AUTHOR), Gilfillan, Chris7 (AUTHOR), Morbey, Claire8 (AUTHOR), Nathow, Thomas9 (AUTHOR), O'Moore‐Sullivan, Trisha10 (AUTHOR), O'Neal, David11 (AUTHOR), Roberts, Adam12 (AUTHOR), Stranks, Stephen13 (AUTHOR), Stuckey, Bronwyn14 (AUTHOR), Vora, Parind15 (AUTHOR), Malpass, Sam16 (AUTHOR), Lloyd, David16 (AUTHOR), Maëstracci‐Beard, Nicole1 (AUTHOR), Buffet, Bénédicte1 (AUTHOR), Kornmann, Gabrielle1 (AUTHOR), Bernard, Corinne1 (AUTHOR) |
| Source: | Diabetes, Obesity & Metabolism. Jul2020, Vol. 22 Issue 7, p1111-1121. 11p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
